This article [12] found that ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma, which confirmed the bright future of combination therapy with vaccination in advanced melanoma patients. This evidence concerns the gene PMEL and melanoma.